Latin America Alzheimers Drug Market Size, Share & Trends Analysis Report By Drug Class (Cholinesterase Inhibitors Donepezil Rivastigmine Galantamine, NMDA Receptor Antagonists Memantine, Combination Drugs Donepezil + Memantine, Anti-Amyloid Monoclonal AntibodiesLecanemab (Leqembi) Aducanumab (Aduhelm) Donanemab (under review) ), By Disease Stage  (Early Stage / Mild Alzheimer€™s, Moderate Alzheimer€™s, Severe Alzheimer€™s, Prodromal / Mild Cognitive Impairment (MCI) ), By Country (UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria) and Forecast, 2026-2034

Latin America Alzheimers Drug Market Trends

Shift Toward Biomarker-Confirmed, Disease-Modifying Therapy

Treatment is moving beyond neurotransmitter management toward amyloid-targeted biologics and earlier intervention. Brazil's Anvisa registered lecanemab in December 2025 for eligible adults with mild cognitive impairment or mild dementia due to Alzheimer's disease and confirmed amyloid pathology. The approved regimen is 10 mg/kg every 2 weeks, delivered by intravenous infusion over approximately 1 hour, creating materially different diagnostic, infusion and monitoring requirements from oral therapies.

Clinical infrastructure is consequently becoming more important. The pivotal evidence reviewed in Brazil involved 1,795 participants, with an efficacy subgroup of 1,521 patients evaluated over 18 months. Meanwhile, a 2026 Brazilian study involving 9,412 adults aged 50+ reported dementia prevalence of 9.6% and a predictive-model accuracy of 70.3%, illustrating growing emphasis on scalable identification and risk stratification alongside pharmacotherapy.

Latin America Alzheimers Drug Market Drivers

Ageing Populations and Earlier Therapeutic Intervention Expand Treatment Requirements

The transition toward early-stage intervention broadens the clinically addressable treatment pathway from established dementia into MCI populations. Brazil's lecanemab authorization covers both MCI and mild dementia with confirmed amyloid pathology, while treatment requires 26 infusions annually under a biweekly schedule and approximately 1 hour per infusion. The Brazilian dementia study's 9.6% prevalence among adults aged 50+ and odds ratio of 11.00 among people aged 90+ illustrate the strong age-related burden supporting sustained pharmaceutical and neurological-care requirements.

Latin America Alzheimers Drug Market Restraints

Diagnostic, Infusion and Safety Requirements Limit Broad Access

Disease-modifying biologics require more infrastructure than established oral drugs. Lecanemab requires confirmed amyloid pathology, ApoE-related patient selection, 10 mg/kg dosing, administration once every 2 weeks, and approximately 1 hour of infusion time. This implies roughly 26 treatment visits per year, excluding diagnostic and monitoring appointments. Such requirements can constrain penetration outside major neurological centers, particularly where imaging, specialist and infusion capacity remain uneven.

Latin America Alzheimers Drug Market Opportunities

Disease-Modifying Biologics Open a New Early-Stage Treatment Pathway

Brazil's authorization of lecanemab creates an opportunity for neurology centers, infusion providers, biomarker diagnostics and specialist pharmacies. The pivotal study enrolled 1,795 patients and assessed outcomes over 18 months, while the approved regimen requires 10 mg/kg every 2 weeks. Expansion of eligible-patient identification could therefore generate demand across multiple healthcare touchpoints rather than pharmaceutical dispensing alone.

Challenges in Latin America Alzheimers Drug Market

Clinical Evidence, Affordability and Commercial Sustainability Remain Critical

The therapeutic landscape remains commercially demanding. Biogen discontinued Aduhelm development and commercialization in 2024 and recorded a USD 60 million program-closure charge, while the therapy had initially carried an annual U.S. list price of USD 56,000, subsequently reduced to roughly USD 28,200. These benchmarks demonstrate how efficacy interpretation, reimbursement and affordability can materially influence adoption even after regulatory authorization.

Latin America Alzheimers Drug Market Segmentation

The market is segmented by drug class, disease stage, mechanism of action, drug type, distribution channel and end user. Within quantified drug classes, cholinesterase inhibitors dominate at approximately 44.48% of 2026 revenue, followed by NMDA receptor antagonists at 21.98%, while anti-amyloid monoclonal antibodies record the highest supplied CAGR at 6.64%.

By Drug Class

Cholinesterase inhibitors, including donepezil, rivastigmine and galantamine, form the largest quantified class, increasing from USD 168.54 million in 2026 to USD 273.33 million by 2034 at 6.23% CAGR. Their 2026 contribution is approximately 44.48% of the drug-class total.

Anti-amyloid monoclonal antibodies, including lecanemab and other amyloid-targeting therapies, constitute the fastest-growing quantified class at 6.64% CAGR, compared with 6.61% for NMDA receptor antagonists, 6.31% for tau aggregation inhibitors and 6.11% for combination drugs.

By Disease Stage

Early/mild Alzheimer's, moderate Alzheimer's, severe Alzheimer's and prodromal/MCI constitute the disease-stage segmentation. Quantified drug-class data show the largest therapeutic category at USD 168.54 million in 2026 and USD 273.33 million in 2034 at 6.23% CAGR, providing the principal commercial base across disease stages.

The fastest quantified therapeutic expansion relevant to earlier-stage treatment is anti-amyloid monoclonal antibodies at 6.64% CAGR. No separate disease-stage revenue or CAGR was supplied; therefore, stage-specific monetary values are not imputed.

By Mechanism of Action

The segmentation covers amyloid-beta inhibitors, tau protein modulators, neurotransmitter modifiers, anti-inflammatory agents, mitochondrial stabilizers and synaptic-function enhancers. Cholinesterase inhibitors remain the largest quantified drug class at USD 168.54 million in 2026, reaching USD 273.33 million by 2034 at 6.23% CAGR.

Amyloid-directed monoclonal antibodies provide the fastest quantified proxy for mechanism-level expansion at 6.64% CAGR. Separate mechanism-of-action revenue figures were not provided and are therefore not estimated.

By Drug Type

Drug type comprises biologics and small molecules. The established small-molecule-oriented cholinesterase inhibitor class generates USD 168.54 million in 2026 and reaches USD 273.33 million by 2034 at 6.23% CAGR.

Biologic momentum is represented by anti-amyloid monoclonal antibodies, the fastest-growing quantified drug class at 6.64% CAGR, compared with 6.23% for cholinesterase inhibitors. No independent biologics-versus-small-molecules revenue split was supplied.

By Distribution Channel

Hospital pharmacies, retail pharmacies and online pharmacies constitute the distribution segmentation. Across these channels, the largest quantified drug class represents USD 168.54 million in 2026 and USD 273.33 million by 2034, expanding at 6.23% CAGR.

The 6.64% CAGR for anti-amyloid monoclonal antibodies indicates increasing importance of hospital-linked dispensing and infusion pathways. Channel-specific monetary values were not supplied and are not independently extrapolated.

By End User

Hospitals, specialty clinics and neurology centers, homecare settings, and academic and research institutions form the end-user landscape. The largest quantified therapeutic class rises from USD 168.54 million in 2026 to USD 273.33 million in 2034 at 6.23% CAGR.

Anti-amyloid monoclonal antibodies expand at the fastest quantified rate of 6.64% CAGR, reinforcing the role of specialist neurological and infusion infrastructure. No separate end-user revenue data were supplied.

Latin America Alzheimers Drug Market Counties Outlook

The requested UAE, Turkey, Saudi Arabia, South Africa, Egypt and Nigeria geography is outside Latin America and therefore cannot be reconciled with the mandatory Latin America dataset. The country outlook consequently follows the supplied Latin America scope: Brazil, Mexico, Argentina, Colombia and Chile.

Brazil

Brazil represents approximately 41.81% of the 2026 country total at USD 158.50 million, rising to USD 262.71 million in 2034 at 6.52% CAGR. It contributes the largest incremental value among supplied countries, adding USD 104.21 million between 2026 and 2034.

Mexico

Mexico contributes approximately 31.79% in 2026, with revenue of USD 120.51 million. The country reaches USD 196.32 million by 2034 at 6.29% CAGR, adding USD 75.81 million during the forecast period.

Argentina

Argentina accounts for approximately 10.03% of 2026 revenue, generating USD 38.01 million. Revenue reaches USD 62.25 million by 2034 at 6.36% CAGR, representing an absolute increase of USD 24.24 million.

Colombia

Colombia contributes approximately 7.99% in 2026 at USD 30.30 million and is projected to reach USD 49.52 million by 2034. Its 6.33% CAGR supports an incremental USD 19.22 million through the forecast horizon.

Chile

Chile represents approximately 8.39% of the 2026 country total at USD 31.80 million. It reaches USD 52.24 million by 2034 at 6.40% CAGR, adding USD 20.44 million.

Top players in Latin America Alzheimers Drug Market

• Eisai Co., Ltd.
• Biogen Inc.
• Eli Lilly and Company
• AbbVie Inc.
• Novartis AG
• Johnson & Johnson
• Pfizer Inc.
• Roche Holding AG
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.

Top Two Companies

• Eisai Co., Ltd.

Eisai holds a strategically important position through Leqembi, developed with Biogen. Brazil's Anvisa registered the biologic in December 2025 for selected adults with MCI or mild Alzheimer's dementia and confirmed amyloid pathology. The therapy is administered at10 mg/kg every 2 weeks, with each infusion lasting approximately1 hour. A company-specific Latin America revenue share percentage has not been supplied or reliably disclosed, so no unsupported percentage is assigned. Its positioning is strengthened by first-mover access to Brazil's emerging disease-modifying treatment pathway.

• Biogen Inc.

Biogen remains positioned in disease-modifying Alzheimer's therapy through its collaboration on Leqembi while redirecting resources away from Aduhelm. In January 2024, Biogen announced discontinuation of Aduhelm development and commercialization and prioritized Leqembi plus tau-directed programs including BIIB080 and BIIB113. A verified company-level Latin America percentage share is not publicly established in the supplied information and is therefore not fabricated. The strategy shifts Biogen toward amyloid and tau modalities while reducing exposure to an unsuccessful commercialization program.

Recent Developments in Latin America Alzheimers Drug Market

• 2026:Brazil confirmed availability authorization for Leqembi following Anvisa's December 2025 registration; treatment targets eligible patients with MCI or mild dementia and uses10 mg/kginfusions every2 weeks.
• 2025:Anvisa formally registered Leqem onDecember 22, 2025, establishing Brazil as an important Latin America market for amyloid-targeted disease-modifying treatment.
• 2025:Lecanemab's international regulatory footprint expanded, including European Commission authorization in April 2025 for eligible early Alzheimer's patients, supporting broader validation of the therapeutic class.

Research Methodology

The analysis uses the supplied 2025, 2026 and 2034 country and drug-class datasets as the mandatory quantitative foundation. Country shares were calculated against the supplied 2026 country total of USD 379.12 million, while drug-class shares were calculated against the separately supplied 2026 drug-class total of USD 378.88 million. The USD 0.24 million difference between these two supplied totals is retained rather than normalized. Forecast CAGRs are reproduced directly from the input data, while calculated percentages use the corresponding supplied totals. Qualitative treatment, regulatory and competitive observations are cross-checked against regulatory, corporate and clinical sources; unsupported production, company-share, disease-stage, channel and end-user figures are deliberately not fabricated.